* ASTRAZENECA PLC - LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA
* ASTRAZENECA - LYNPARZA GRANTED PRIORITY REVIEW IN US FOR BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER Source text for Eikon: Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}